

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

RECEIVED
JUL 10 2003
TECH CENTER



1600

RAW SEQUENCE LISTING

DATE: 07/03/2003

PATENT APPLICATION: US/09/653,761A

TIME: 14:16:49

Input Set : A:\2179.2002-000 (2ndSubSeq).txt

Output Set: N:\CRF4\07032003\I653761A.raw

4 <110> APPLICANT: Fodor, Stephen P.A.
5 Read, J. Leighton
6 Stryer, Lubert
7 Pirrung, Michael C.
9 <120> TITLE OF INVENTION: Polypeptide Arrays (As Amended)
12 <130> FILE REFERENCE: 2719.2004-000
14 <140> CURRENT APPLICATION NUMBER: 09/653,761A
15 <141> CURRENT FILING DATE: 2000-09-01
17 <150> PRIOR APPLICATION NUMBER: 09/557,875
18 <151> PRIOR FILING DATE: 2000-04-24
20 <150> PRIOR APPLICATION NUMBER: 09/056,927
21 <151> PRIOR FILING DATE: 1998-04-08
23 <150> PRIOR APPLICATION NUMBER: 08/670,118
24 <151> PRIOR FILING DATE: 1996-06-25
26 <150> PRIOR APPLICATION NUMBER: 08/168,904
27 <151> PRIOR FILING DATE: 1993-12-15
29 <150> PRIOR APPLICATION NUMBER: 07/624,114
30 <151> PRIOR FILING DATE: 1990-12-06
32 <150> PRIOR APPLICATION NUMBER: 07/362,901
33 <151> PRIOR FILING DATE: 1989-06-07
35 <160> NUMBER OF SEQ ID NOS: 34
37 <170> SOFTWARE: FastSEQ for Windows Version 4.0
39 <210> SEQ ID NO: 1
40 <211> LENGTH: 5
41 <212> TYPE: PRT
42 <213> ORGANISM: Artificial Sequence
44 <220> FEATURE:
45 <223> OTHER INFORMATION: Synthesized Peptide Sequence
47 <400> SEQUENCE: 1
48 Tyr Gly Gly Phe Leu
49 1 5
52 <210> SEQ ID NO: 2
53 <211> LENGTH: 4
54 <212> TYPE: PRT
55 <213> ORGANISM: Artificial Sequence
57 <220> FEATURE:
58 <223> OTHER INFORMATION: Synthesized Peptide Sequence
60 <400> SEQUENCE: 2
61 Gly Gly Phe Leu
62 1
65 <210> SEQ ID NO: 3
66 <211> LENGTH: 5
67 <212> TYPE: PRT

p.6

ENTERED

RAW SEQUENCE LISTING

DATE: 07/03/2003

PATENT APPLICATION: US/09/653,761A

TIME: 14:16:49

Input Set : A:\2179.2002-000 (2ndSubSeq).txt

Output Set: N:\CRF4\07032003\I653761A.raw

68 <213> ORGANISM: Artificial Sequence
70 <220> FEATURE:
71 <223> OTHER INFORMATION: Synthesized Peptide Sequence
73 <400> SEQUENCE: 3
74 Pro Gly Gly Phe Leu
75 1 5
78 <210> SEQ ID NO: 4
79 <211> LENGTH: 6
80 <212> TYPE: PRT
81 <213> ORGANISM: Artificial Sequence
83 <220> FEATURE:
84 <223> OTHER INFORMATION: Synthesized Peptide Sequence
86 <400> SEQUENCE: 4
87 Tyr Pro Gly Gly Phe Leu
88 1 5
91 <210> SEQ ID NO: 5
92 <211> LENGTH: 5
93 <212> TYPE: PRT
94 <213> ORGANISM: Artificial Sequence
96 <220> FEATURE:
97 <223> OTHER INFORMATION: Synthesized Peptide Sequence
99 <400> SEQUENCE: 5
100 Tyr Ala Gly Phe Leu
101 1 5
104 <210> SEQ ID NO: 6
105 <211> LENGTH: 5
106 <212> TYPE: PRT
107 <213> ORGANISM: Artificial Sequence
109 <220> FEATURE:
110 <223> OTHER INFORMATION: Synthesized Peptide Sequence
112 <400> SEQUENCE: 6
113 Tyr Ser Gly Phe Leu
114 1 5
117 <210> SEQ ID NO: 7
118 <211> LENGTH: 5
119 <212> TYPE: PRT
120 <213> ORGANISM: Artificial Sequence
122 <220> FEATURE:
123 <223> OTHER INFORMATION: Synthesized Peptide Sequence
125 <400> SEQUENCE: 7
126 Leu Gly Gly Phe Leu
127 1 5
130 <210> SEQ ID NO: 8
131 <211> LENGTH: 5
132 <212> TYPE: PRT
133 <213> ORGANISM: Artificial Sequence
135 <220> FEATURE:
136 <223> OTHER INFORMATION: Synthesized Peptide Sequence
138 <400> SEQUENCE: 8

RAW SEQUENCE LISTING

DATE: 07/03/2003

PATENT APPLICATION: US/09/653,761A

TIME: 14:16:49

Input Set : A:\2179.2002-000 (2ndSubSeq).txt

Output Set: N:\CRF4\07032003\I653761A.raw

139 Phe Gly Gly Phe Leu
140 1 5
143 <210> SEQ ID NO: 9
144 <211> LENGTH: 5
145 <212> TYPE: PRT
146 <213> ORGANISM: Artificial Sequence
148 <220> FEATURE:
149 <223> OTHER INFORMATION: Synthesized Peptide Sequence
151 <400> SEQUENCE: 9
152 Leu Ala Gly Phe Leu
153 1 5
156 <210> SEQ ID NO: 10
157 <211> LENGTH: 5
158 <212> TYPE: PRT
159 <213> ORGANISM: Artificial Sequence
161 <220> FEATURE:
162 <223> OTHER INFORMATION: Synthesized Peptide Sequence
164 <400> SEQUENCE: 10
165 Phe Ala Gly Phe Leu
166 1 5
169 <210> SEQ ID NO: 11
170 <211> LENGTH: 5
171 <212> TYPE: PRT
172 <213> ORGANISM: Artificial Sequence
174 <220> FEATURE:
175 <223> OTHER INFORMATION: Synthesized Peptide Sequence
177 <400> SEQUENCE: 11
178 Trp Gly Gly Phe Leu
179 1 5
182 <210> SEQ ID NO: 12
183 <211> LENGTH: 5
184 <212> TYPE: PRT
185 <213> ORGANISM: Artificial Sequence
187 <220> FEATURE:
188 <223> OTHER INFORMATION: Synthesized Peptide Sequence
190 <400> SEQUENCE: 12
191 Tyr Pro Gly Phe Leu
192 1 5
195 <210> SEQ ID NO: 13
196 <211> LENGTH: 5
197 <212> TYPE: PRT
198 <213> ORGANISM: Artificial Sequence
200 <220> FEATURE:
201 <223> OTHER INFORMATION: Synthesized Peptide Sequence
203 <400> SEQUENCE: 13
204 Leu Pro Gly Phe Leu
205 1 5
208 <210> SEQ ID NO: 14
209 <211> LENGTH: 5

RAW SEQUENCE LISTING

DATE: 07/03/2003

PATENT APPLICATION: US/09/653,761A

TIME: 14:16:49

Input Set : A:\2179.2002-000 (2ndSubSeq).txt

Output Set: N:\CRF4\07032003\I653761A.raw

210 <212> TYPE: PRT
211 <213> ORGANISM: Artificial Sequence
213 <220> FEATURE:
214 <223> OTHER INFORMATION: Synthesized Peptide Sequence
216 <400> SEQUENCE: 14
217 Trp Pro Gly Phe Leu
218 1 5
221 <210> SEQ ID NO: 15
222 <211> LENGTH: 5
223 <212> TYPE: PRT
224 <213> ORGANISM: Artificial Sequence
226 <220> FEATURE:
227 <223> OTHER INFORMATION: Synthesized Peptide Sequence
229 <400> SEQUENCE: 15
230 Trp Ala Gly Phe Leu
231 1 5
234 <210> SEQ ID NO: 16
235 <211> LENGTH: 5
236 <212> TYPE: PRT
237 <213> ORGANISM: Artificial Sequence
239 <220> FEATURE:
240 <223> OTHER INFORMATION: Synthesized Peptide Sequence
242 <400> SEQUENCE: 16
243 Leu Ser Gly Phe Leu
244 1 5
247 <210> SEQ ID NO: 17
248 <211> LENGTH: 5
249 <212> TYPE: PRT
250 <213> ORGANISM: Artificial Sequence
252 <220> FEATURE:
253 <223> OTHER INFORMATION: Synthesized Peptide Sequence
255 <400> SEQUENCE: 17
256 Phe Ser Gly Phe Leu
257 1 5
260 <210> SEQ ID NO: 18
261 <211> LENGTH: 5
262 <212> TYPE: PRT
263 <213> ORGANISM: Artificial Sequence
265 <220> FEATURE:
266 <223> OTHER INFORMATION: Synthesized Peptide Sequence
268 <400> SEQUENCE: 18
269 Trp Ser Gly Phe Leu
270 1 5
273 <210> SEQ ID NO: 19
274 <211> LENGTH: 5
275 <212> TYPE: PRT
276 <213> ORGANISM: Artificial Sequence
278 <220> FEATURE:
279 <223> OTHER INFORMATION: Synthesized Peptide Sequence

RAW SEQUENCE LISTING

DATE: 07/03/2003

PATENT APPLICATION: US/09/653,761A

TIME: 14:16:49

Input Set : A:\2179.2002-000 (2ndSubSeq).txt

Output Set: N:\CRF4\07032003\I653761A.raw

```

281 <400> SEQUENCE: 19
282 Phe Pro Gly Phe Leu
283 1 5
286 <210> SEQ ID NO: 20
287 <211> LENGTH: 5
288 <212> TYPE: PRT
289 <213> ORGANISM: Artificial Sequence
291 <220> FEATURE:
292 <223> OTHER INFORMATION: Synthesized Peptide Sequence
W--> 294 <221> NAME/KEY: VARIANT
295 <222> LOCATION: (2)...(2)
296 <223> OTHER INFORMATION: Xaa = D amino acid alanine
W--> 298 <400> 20
W--> 299 Tyr Xaa Gly Phe Leu
300 1 5
303 <210> SEQ ID NO: 21
304 <211> LENGTH: 5
305 <212> TYPE: PRT
306 <213> ORGANISM: Artificial Sequence
308 <220> FEATURE:
309 <223> OTHER INFORMATION: Synthesized Peptide Sequence
W--> 311 <221> NAME/KEY: VARIANT
312 <222> LOCATION: (2)...(2)
313 <223> OTHER INFORMATION: Xaa = D amino acid serine
W--> 315 <400> 21
W--> 316 Tyr Xaa Gly Phe Leu
317 1 5
320 <210> SEQ ID NO: 22
321 <211> LENGTH: 5
322 <212> TYPE: PRT
323 <213> ORGANISM: Artificial Sequence
325 <220> FEATURE:
326 <223> OTHER INFORMATION: Synthesized Peptide Sequence
W--> 328 <221> NAME/KEY: VARIANT
329 <222> LOCATION: (2)...(2)
330 <223> OTHER INFORMATION: Xaa = D amino acid proline
W--> 332 <400> 22
W--> 333 Tyr Xaa Gly Phe Leu
334 1 5
337 <210> SEQ ID NO: 23
338 <211> LENGTH: 5
339 <212> TYPE: PRT
340 <213> ORGANISM: Artificial Sequence
342 <220> FEATURE:
343 <223> OTHER INFORMATION: Synthesized Peptide Sequence
W--> 345 <221> NAME/KEY: VARIANT
346 <222> LOCATION: (1)...(1)
347 <223> OTHER INFORMATION: Xaa = D amino acid phenylalanine
W--> 349 <400> 23

```

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/653,761A

DATE: 07/03/2003
TIME: 14:16:50

Input Set : A:\2179.2002-000 (2ndSubSeq).txt
Output Set: N:\CRF4\07032003\I653761A.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:20; Xaa Pos. 2
Seq#:21; Xaa Pos. 2
Seq#:22; Xaa Pos. 2
Seq#:23; Xaa Pos. 1
Seq#:24; Xaa Pos. 1
Seq#:25; Xaa Pos. 1,2
Seq#:26; Xaa Pos. 1
Seq#:27; Xaa Pos. 1,2
Seq#:28; Xaa Pos. 1,2
Seq#:29; Xaa Pos. 1,2
Seq#:30; Xaa Pos. 1,2
Seq#:31; Xaa Pos. 1,2
Seq#:32; Xaa Pos. 1,2
Seq#:33; Xaa Pos. 1,2
Seq#:34; Xaa Pos. 1,2